Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different approach – looking at drugs that already have FDA approval to see what other conditions they might treat.

A breakthrough in precision and customized medicine, announced by AMPEL BioSolutions, may update how physicians treat patients with various illnesses, including cancer, infectious disorders, and autoimmune.